Comparative Pharmacology
Head-to-head clinical analysis: FLUDARA versus KADCYLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARA versus KADCYLA.
FLUDARA vs KADCYLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Deslanoside
"Fludarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFludarabine + Acetyldigitoxin
"Fludarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent